BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smorodinsky E, Ansdell DS, Foster ZW, Mazhar SM, Cruite I, Wolfson T, Sugay SB, Iussich G, Shiehmorteza M, Kono Y, Kuo A, Sirlin CB. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging 2015;41:1259-67. [PMID: 24811860 DOI: 10.1002/jmri.24650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Alabousi M, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: Radiology In Training. Radiology 2021;300:279-84. [PMID: 34060939 DOI: 10.1148/radiol.2021210044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol. 2016;51:701-705. [PMID: 26885631 DOI: 10.1097/rli.0000000000000259] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
3 Lunyera J, Mohottige D, Alexopoulos AS, Campbell H, Cameron CB, Sagalla N, Amrhein TJ, Crowley MJ, Dietch JR, Gordon AM, Kosinski AS, Cantrell S, Williams JW Jr, Gierisch JM, Ear B, Goldstein KM. Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review. Ann Intern Med 2020;173:110-9. [PMID: 32568573 DOI: 10.7326/M20-0299] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Chen WT, Liang JL, Chen MH, Liao CC, Huang TL, Chen TY, Tsang LL, Ou HY, Hsu HW, Lazo MZ. Noncontrast Magnetic Resonance Angiography Using Inflow Sensitive Inversion Recovery Technique for Vascular Evaluation in Pre-liver Transplantation Recipients. Transplant Proc. 2016;48:1032-1035. [PMID: 27320549 DOI: 10.1016/j.transproceed.2015.12.083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Forghani R. Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. Top Magn Reson Imaging 2016;25:163-9. [PMID: 27367314 DOI: 10.1097/RMR.0000000000000095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
7 Martin DR, Kalb B, Mittal A, Salman K, Vedantham S, Mittal PK. No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease. Radiology 2018;286:113-9. [DOI: 10.1148/radiol.2017170102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
8 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2021;298:28-35. [PMID: 33170103 DOI: 10.1148/radiol.2020202903] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
9 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
10 Lauenstein T, Ramirez-Garrido F, Kim YH, Rha SE, Ricke J, Phongkitkarun S, Boettcher J, Gupta RT, Korpraphong P, Tanomkiat W, Furtner J, Liu PS, Henry M, Endrikat J. Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Invest Radiol 2015;50:416-22. [PMID: 25756684 DOI: 10.1097/RLI.0000000000000145] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 7.8] [Reference Citation Analysis]
11 Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ 2nd, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. AJR Am J Roentgenol. 2015;205:469-478. [PMID: 26295633 DOI: 10.2214/ajr.14.14268] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
12 Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med 2020;180:223-30. [PMID: 31816007 DOI: 10.1001/jamainternmed.2019.5284] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 62.0] [Reference Citation Analysis]
13 Michaely HJ, Aschauer M, Deutschmann H, Bongartz G, Gutberlet M, Woitek R, Ertl-Wagner B, Kucharczyk W, Hammerstingl R, De Cobelli F, Rosenberg M, Balzer T, Endrikat J. Gadobutrol in Renally Impaired Patients: Results of the GRIP Study. Invest Radiol 2017;52:55-60. [PMID: 27529464 DOI: 10.1097/RLI.0000000000000307] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
14 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med 2021;3:142-50. [PMID: 33604544 DOI: 10.1016/j.xkme.2020.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
15 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:136-50. [PMID: 29706252 DOI: 10.1016/j.carj.2017.11.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
16 Huang PH, Liao CC, Chen MH, Huang TL, Chen CL, Ou HY, Cheng YF. Noncontrast Magnetic Resonance Angiography Clinical Application in Pre-Liver Transplant Recipients With Impaired Renal Function. Liver Transpl 2020;26:196-202. [PMID: 31715655 DOI: 10.1002/lt.25677] [Reference Citation Analysis]
17 Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging 2017;46:338-53. [PMID: 28083913 DOI: 10.1002/jmri.25625] [Cited by in Crossref: 168] [Cited by in F6Publishing: 132] [Article Influence: 42.0] [Reference Citation Analysis]